Clinical Trial Update: REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating empagliflozin in type 2 diabetes and chronic kidney disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Diseases | Phase 4 | Status: WITHDRAWN